Hewamana, Saman, Lin, Thet Thet, Rowntree, Clare, Karunanithi, Kamaraj, Pratt, Guy, Hills, Robert Kerrin  ORCID: https://orcid.org/0000-0003-0166-0062, Fegan, Christopher Daniel ORCID: https://orcid.org/0000-0001-9685-0621, Brennan, Paul ORCID: https://orcid.org/0000-0001-8792-0499 and Pepper, Christopher John
2009.
Rel A is an independent biomarker of clinical outcome in chronic lymphocytic leukemia.
Journal of Clinical Oncology
27
(5)
, pp. 763-769.
10.1200/JCO.2008.19.1114
|
Abstract
Purpose: We recently demonstrated the biologic importance of the nuclear factor kappa B (NF-κB) subunit Rel A in chronic lymphocytic leukemia (CLL) and hypothesized that Rel A DNA binding would have prognostic significance in this disease. Patients and Methods: Rel A DNA binding was quantified in nuclear extracts derived from 131 unselected CLL patient samples using a quantitative DNA-binding enzyme-linked immunosorbent assay–based method. We then investigated the ability of Rel A to predict for the requirement for treatment and survival and compared our findings with other established prognostic markers. Results: Rel A DNA binding was strongly associated with advanced Binet stage (P < .0001) but did not correlate with immunoglobulin VH (IgVH) mutation status (P = .25), CD38 expression (P = .87), or zeta-chain–associated protein kinase 70 (ZAP-70) expression (P = .55). It was predictive of time to first treatment (P = .02) and time to subsequent treatment (P = .0001). In addition, Rel A was the most predictive marker of survival both from date of diagnosis (hazard ratio [HR], 9.1; P = .01) and date of entry into the study (HR, 3.9; P = .05) and retained prognostic significance in multivariate analysis for both time to first treatment and overall survival in the presence of Binet stage, IgVH mutation status, CD38, and ZAP-70. Conclusion: Rel A is an independent prognostic marker of survival in CLL and seems to have the unique capacity to predict the duration of response to therapy. Prospective assessment of Rel A as a marker of clinical outcome and as a therapeutic target are now warranted.
| Item Type: | Article |
|---|---|
| Date Type: | Publication |
| Status: | Published |
| Schools: | Schools > Medicine |
| Subjects: | Q Science > QH Natural history > QH426 Genetics R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology |
| Publisher: | American Society of Clinical Oncology |
| ISSN: | 0732-183X |
| Funders: | Leukemia Research (UK), Leukemia Research Appeal for Wales, Welsh Bone Marrow Transplant Research Fund. |
| Last Modified: | 06 Nov 2022 14:19 |
| URI: | https://orca.cardiff.ac.uk/id/eprint/29208 |
Citation Data
Cited 50 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
 |
Edit Item |
Dimensions
Dimensions